Around 77 new oncology drugs were approved by the FDA in the past five years; however,
most cancers remain untreated. Small molecules and antibodies are dominant therapeutic …

A high incidence of cancer has given rise to the development of more anti-tumor drugs. From
2015 to 2020, fifty-six new small-molecule anticancer drugs, divided into ten categories …

As one of the most lethal malignancies, lung cancer is considered to account for
approximately one-fifth of all malignant tumours-related deaths worldwide. This study reports …

Background: Copy number alterations are common genetic lesions in cancer. In squamous
non-small cell lung carcinomas, the most common copy-number-altered loci are at …

The combination of shikonin (SKN) and gefitinib (GFB) can reverse the drug resistance of
lung cancer cells by affecting energy metabolism. However, the poor solubility of SKN and …

Lung cancer is a highly aggressive neoplasm and, despite the development of recent
therapies, tumor progression and recurrence following the initial response remains …

Central nervous system (CNS) metastases from epithelial ovarian cancer (EOC) are rare.
We investigated the clinico-pathological prognostic factors of patients with CNS metastases …

Studies have reported that B-and T-lymphocyte attenuator (BTLA) polymorphisms may be
associated with the risk to different cancers. However, the correlation between those …

Lung adenocarcinoma is the most common subtype of non‑small cell lung carcinoma.
Tanshinone I is an important fat‑soluble component in the extract of Salvia miltiorrhiza that …

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In spite of great
advances, treatment of the disease is a medical challenge. Epidermal-growth factor receptor …